Updated statement by the German Society for Pediatric and Adolescent Rheumatology (GKJR) on the FDA's report regarding malignancies in anti-TNF-treated patients from Aug. 4, 2009;Aktualisierte Stellungnahme der GKJR zur Meldung der FDA über Fälle von Malignomen bei Anti-TNF-behandelten Patienten vom 04.08.2009

Zeitschrift fur Rheumatologie

Volumn 69, Issue 6, 2010, Pages 561-567

  Horneff, G ^a   Hospach, T ^b   Dannecker, G ^b   Foll D ^c   Haas, J P ^d   Girschick, H J ^e   Huppertz, H I ^f   Keitzer, R ^g   Laws, H J ^h   Michels, H ⁱ   Minden, K ^g   Trauzeddel, R ^a  

^a Asklepios Klinik   (Germany)

^b OLGAHOSPITAL   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d German Center for Pediatric and Adolescent Rheumatology   (Germany)

^e Vivantes Klinikum Friedrichshain   (Germany)

^f Zentralkrankenhaus   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h Universitätskinderklinik Düsseldorf   (Germany)

ⁱ Helios Klinikum Berlin Buch ^*

Author keywords

Adolescents; Children; Inflammatory bowel disease; Juvenile idiopathic arthritis; Malignancy; Tumor necrosis factor (TNF) blockers

Indexed keywords

ADALIMUMAB; CYCLOPHOSPHAMIDE; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

CANCER RISK; CHILDHOOD CANCER; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JUVENILE RHEUMATOID ARTHRITIS; LEUKEMIA; LYMPHOMA; MEDICAL DOCUMENTATION; MEDICAL SOCIETY; PATIENT INFORMATION; REVIEW; RISK FACTOR; TREATMENT INDICATION; TREATMENT WITHDRAWAL; TUMOR;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; ARTHRITIS, JUVENILE RHEUMATOID; BIOLOGICAL PRODUCTS; CHILD; HUMANS; LEUKEMIA; LYMPHOMA; NEOPLASMS; OFF-LABEL USE; SOCIETIES, MEDICAL; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; YOUNG ADULT;

EID: 77956344683     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00393-009-0600-x     Document Type: Review

References (29)

1. Amgen (2009) Amgen and Wyeth statement on FDA announcement about tumor necrosis factor (TNF) blockers. http://wwwext.amgen.com/media/media-pr-detail. jsp?year=2009&releaseID=1316767
2. Askling J, Fored CM, Baecklund E et al (2005) Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 64:1414-1420
3. Askling J, Vollenhoven RF van, Granath F et al (2009) Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: Does the risk change with the time since start of treatment? Arthritis Rheum 60:3180-3189
4. Baecklund E, Iliadou A, Askling J et al (2006) Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54:692-701
5. Batzler WU, Giersiepen K, Hentschel S et al (2008) Cancer in Germany 2003-2004. Incidence and trends. In: Katalinic A, Bertz J, Haberland J, Wolf U (Hrsg) 6, 1-113. 2008. Berlin, Robert-Koch-Institut, Berlin, und Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. http://www.ekr.med.uni- erlangen.de/GEKID/Doc/kid2008-english.pdf
6. Bernatsky S, Rosenberg A, Oen KG et al (2009) Malignancy in juvenile idiopathic arthritis. Arthritis Rheum 60(Suppl), Abstract 250
7. Cucchiara S, Escher JC, Hildebrand H et al (2009) Pediatric inflammatory bowel diseases and the risk of lymphoma: should we revise our treatment strategies? J Pediatr Gastroenterol Nutr 48:257-267
8. Franklin J, Lunt M, Bunn D et al (2006) Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis. Ann Rheum Dis 65:617-622
9. Giannini EH, Ilowite NT, Lovell DJ et al (2009) Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 60:2794-2804
10. Guellac N, Niehues T (2008) Interdisziplinäre S2-Leitlinie der juvenilen idiopathischen Arthritis. Klin Pädiatr 220:392-402
11. Horneff G (2006) Einsatz von Biologika bei der juvenilen idiopathischen Arthritis. Konsensus-Statement des 7. Wörlitzer Expertengespräches 2004 für die Arbeitsgemeinschaft Kinder- und Jugendrheumatologie. Z Rheumatol 65:152-158
12. Horneff G, De Bock F, Foeldvari I et al (2009) Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 68:519-525
13. Horneff G, Schmeling H, Biedermann T et al (2004) The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 63:1638-1644
14. Hospach T, Haas JP, Huppertz HI et al (2009) Stellungnahme der Gesellschaft für Kinder- und Jugendrheumatologie zur Meldung der US-Food and Drug Administration (FDA) über Fälle von Malignomen bei Anti-TNF-behandelten Patienten. Z Rheumatol 68:162-164
15. Kaatsch P, Spix C (2009) Deutsches Kinderkrebsregister. Jahresbericht 2008. Institut für Medizinische Biometrie, Epidemiologie und Informatik (IMBEI), Obere Zahlbacher Strasse 69, 55131 Mainz. http://www. kinderkrebsregister.de
16. Kwon JH, Farrell RJ (2005) The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents. Crit Rev Oncol Hematol 56:169-178
17. Mackey AC, Green L, Leptak C et al (2009) Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr 48:386-388
18. Mackey AC, Green L, Liang LC et al (2007) Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 44:265-267
19. Minden K (2008) Prognose der rheumatischen Erkrankungen im Kindes- und Jugendalter. Kinder- und Jugendarzt 4:258-266
20. Navarro JT, Ribera JM, Mate JL et al (2003) Hepatosplenic T-gammadelta lymphoma in a patient with Crohns disease treated with azathioprine. Leuk Lymphoma 44:531-533
21. Rosh JR, Gross T, Mamula P et al (2007) Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohns disease: a cautionary tale? Inflamm Bowel Dis 13:1024-1030
22. Salloum E, Cooper DL, Howe G et al (1996) Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol 14:1943-1949
23. Thomas E, Brewster DH, Black RJ et al (2000) Risk of malignancy among patients with rheumatic conditions. Int J Cancer 88:497-502
24. U.S. Food and Drug Administration (2008) Early communication about an ongoing safety review of tumor necrosis factor (TNF) blockers (marketed as Remicade, Enbrel, Humira, and Cimzia). http://www.fda.gov/cder/drug/early-comm/ TNF-blockers.htm
25. U.S. Food and Drug Administration (2009) Follow-up to the june 4, 2008 early communication about the ongoing safety review of tumor necrosis factor (TNF) blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi). http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm174449.htm
26. U.S. Food and Drug Administration (2009) Information for healthcare professionals: tumor necrosis factor (TNF) blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi). http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm174474.htm
27. U.S. Food and Drug Administration (2009) Questions and answers - TNF blockers 8/25/2009. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm180694.htm
28. Wolfe F, Michaud K (2004) Lymphoma in rheumatoid arthritis. The effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 50:1740-1751
29. Wolfe F, Michaud K (2007) Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 56:2886-2895